` 002294 (Shenzhen Salubris Pharmaceuticals Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

S
002294
vs
S
Shanghai Composite

Over the past 12 months, Shenzhen Salubris Pharmaceuticals Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +69% compared to the Shanghai Composite's +15% growth.

Stocks Performance
002294 vs Shanghai Composite

Loading
002294
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
002294 vs Shanghai Composite

Loading
002294
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
002294 vs Shanghai Composite

Loading
002294
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Shenzhen Salubris Pharmaceuticals Co Ltd vs Peers

Shanghai Composite
002294
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Shenzhen Salubris Pharmaceuticals Co Ltd
Glance View

Market Cap
61.9B CNY
Industry
Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. stands as a dynamic player in the pharmaceutical landscape, tracing its origins to China’s bustling hub of innovation, Shenzhen. From its inception, Salubris has steadily cultivated a robust portfolio, deeply rooted in the development, production, and commercialization of a wide array of pharmaceutical products. With a steadfast focus on cardiovascular and cerebrovascular medications, the company has adeptly positioned itself to meet significant medical needs, leveraging its expertise to produce both traditional and novel therapies. This focus is complemented by an ambitious expansion into biopharmaceuticals, a sector that holds significant potential for growth. Salubris thrives by combining its innovative R&D capabilities with efficient production processes, ensuring that its offerings not only reach a broad customer base but also adhere to stringent quality standards. The company’s business model revolves around a meticulously crafted combination of research innovation and strategic partnerships. By investing significantly in research and development, Salubris ensures a pipeline filled with promising drugs poised to address prevalent health issues. The company maximizes its revenues through its sales network, which extends beyond domestic borders, tapping into international markets where demand for high-quality pharmaceuticals continues to rise. Additionally, Salubris has been proactive in pursuing collaborations and partnerships, both to bolster its research capabilities and to navigate regulatory landscapes more effectively. By marrying these strategic approaches, Salubris not only sustains its competitive edge but also ensures a steady growth trajectory, embodying a business narrative that resonates with resilience and forward-thinking ambition.

Intrinsic Value
25.85 CNY
Overvaluation 53%
Intrinsic Value
Price
S
Back to Top